Laura Ciaffi

Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon

Alexandra Calmy, Tamara Tovar-Sanchez, Charles Kouanfack et al. · The Lancet HIV · 2020 · 155 citations

Open Label, Week 96, Treatment And Prevention +10

BURULI ULCER DISEASE IN CAMEROON REDISCOVERED

J Noeske, Christopher Kuaban, Simona Rondini et al. · American Journal of Tropical Medicine and Hygiene · 2004 · 87 citations

Active Bu, Buruli Ulcer, Klebsiella Pneumoniae +7

Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial

Laura Ciaffi, Sinata Koulla‐Shiro, Adrien Sawadogo et al. · The Lancet HIV · 2017 · 71 citations

Lamivudine Dual Therapy, Superiority Trial, Protease Inhibitor +9

SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon

Kenechukwu Obumneme Samuel Nwosu, Joseph Fokam, Franck Wanda et al. · Nature Communications · 2021 · 61 citations · Full text

Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial

Maryline Bonnet, Nilesh Bhatt, Elisabeth Baudin et al. · The Lancet Infectious Diseases · 2013 · 50 citations

Treatment And Prevention, Antiviral Therapy, Tuberculosis +7